Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study

By sjmartinez • October 23, 2023

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2023 Oct 20:S0190-9622(23)03029-3. doi: 10.1016/j.jaad.2023.10.026. Epub ahead of print. PMID: 37866456.

Tags: atopic dermatitis, Dermatology, EASI, eblasakimab, IL-13, IL-4, moderate-to-severe AD, pruritus, Publications, type 2 inflammation

Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-Reported Outcomes by Baseline[...]

Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial

Zinter MS, Taylor CS, Markovic D, Pellegrini M, Wong K, Balliu B, Gala KP, Asaro LA, Nadkarni VM, McQuillen PS, Vangala SS, Sinha P, Matthay[...]

Cutaneous manifestation of metastatic papillary thyroid carcinoma

Peng D, Dong E, Martinez D, Kang Y, Wong D, Holland V. Cutaneous manifestation of metastatic papillary thyroid carcinoma. JAAD Case Rep. 2025 Apr 11;60:129-131.[...]